Scholars@Duke

Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC)

Publication ,  Conference
Bullock, KE; Hurwitz, HI; Uronis, HE; Morse, MA; Blobe, GC; Hsu, SD; Zafar, SY; Nixon, AB; Howard, LA; Bendell, JC
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2009
Link to item

Duke Scholars

Hope Elizabeth Uronis
Author Hope Elizabeth Uronis Medicine, Medical Oncology
Michael Aaron Morse
Author Michael Aaron Morse Medicine, Medical Oncology
Gerard Conrad Blobe
Author Gerard Conrad Blobe Medicine, Medical Oncology
Syed Yousuf Zafar
Author Syed Yousuf Zafar Medicine, Medical Oncology
Andrew Benjamin Nixon
Author Andrew Benjamin Nixon Medicine, Medical Oncology

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2009

Volume

27

Issue

15

Location

Orlando, FL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bullock, K. E., Hurwitz, H. I., Uronis, H. E., Morse, M. A., Blobe, G. C., Hsu, S. D., … Bendell, J. C. (2009). Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 27). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
Bullock, K. E., H. I. Hurwitz, H. E. Uronis, M. A. Morse, G. C. Blobe, S. D. Hsu, S. Y. Zafar, A. B. Nixon, L. A. Howard, and J. C. Bendell. “Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
Bullock KE, Hurwitz HI, Uronis HE, Morse MA, Blobe GC, Hsu SD, et al. Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2009.
Bullock, K. E., et al. “Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 27, no. 15, AMER SOC CLINICAL ONCOLOGY, 2009.
Bullock KE, Hurwitz HI, Uronis HE, Morse MA, Blobe GC, Hsu SD, Zafar SY, Nixon AB, Howard LA, Bendell JC. Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2009.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2009

Volume

27

Issue

15

Location

Orlando, FL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences